Plastic and Reconstructive Surgery • March 2018 challenging, as radiation therapy-induced changes to the recipient bed (i.e., hypovascularity) result in poorer fat graft survival. 10, 11 Cell-based strategies to enhance volume retention, through enrichment of fat grafts with additional adipose-derived stromal cells, have been shown to improve outcomes, 11 but translation of this approach remains difficult because of known heterogeneity of the stromal vascular fraction and regulatory hurdles.
As an alternative, deferoxamine has been studied as an angiogenic and antioxidant agent with the potential to improve fat graft survival. 12 Deferoxamine, a U.S. Food and Drug Administration-approved iron chelator for treating acute iron poisoning and chronic iron overload associated with frequent blood transfusions, has also been demonstrated to increase hypoxia-inducible factor-1α (HIF-1α) activity and enhance expression of angiogenic growth factors. 13, 14 Studies have also shown local injection of deferoxamine to improve ischemic flap survival in both mouse and pig models, 15, 16 with increased skin flap blood perfusion and capillary density noted in deferoxamine-treated animals. 15 Also, in the setting of irradiated bone, multiple reports have found deferoxamine to promote bone regeneration following distraction osteogenesis through enhanced vascularity. [17] [18] [19] Given this ability for local deferoxamine application to promote revascularization, we investigated the potential for deferoxamine preconditioning of irradiated tissue to enhance subsequent fat graft retention.
MATERIALS AND METHODS

Animal Irradiation Model and Post-Radiation Therapy Treatment
All studies were performed in accordance with Stanford University animal guidelines. Adult 60-day-old male Crl:NU-Fox1
NU immunocompromised mice were used for experiments in this study. Twelve mice were treated with a total of 30 Gy of external beam radiation, delivered as six fractionated doses of 5 Gy each over 12 days, followed by 5 weeks of recovery. An additional six nonirradiated mice were used as healthy controls for laser Doppler analysis and skin analysis. Irradiated mice were divided into two treatment groups: a deferoxamine experimental group and a saline control group. After recovery, mice underwent injection of either deferoxamine (1 mg in 100 μl of saline) or 100 μl of saline alone beneath the dermis every other day for a total of seven treatments (Fig. 1) .
Laser Doppler Analysis
Laser Doppler analysis was performed to measure perfusion at the irradiated site. A Perimed PIM 3 laser Doppler perfusion imager (Järfälla, Sweden) was used. The signal generated by the laser Doppler analysis (i.e., laser Doppler perfusion index) was used for comparative purposes. The laser Doppler perfusion index is a product of the blood cell velocity and concentration, and is represented by a color spectrum, with black/ dark blue representing low perfusion and red representing high perfusion. Laser Doppler analysis was performed before irradiation, after completion of irradiation and recovery, and then 24 hours after each treatment with deferoxamine or saline. Laser Doppler analysis was also performed every 2 weeks after fat grafting. Five images were taken of each mouse and the average laser Doppler perfusion index of the five images was recorded.
Fat Grafting and Fat Graft Volume Analysis
After informed consent was obtained, lipoaspirate was obtained from three healthy female donors (aged 45, 49, and 51 years) with no other medical comorbidities under an approved institutional review board protocol (number 2188). Lipoaspirate was allowed to settle for 15 minutes for layers to separate by gravity sedimentation, and then oil and blood layers were removed by vacuum aspiration. The remaining fat layer was centrifuged at 1300 relative centrifugal force for 3 minutes at 4°C. Any remaining oil and blood was again removed and the remaining fat was transferred into 1-cc syringes for injection through a 14-gauge needle. Fat grafting was performed beneath the scalp by creating a subcutaneous tunnel with the needle and then injecting 200 μl of lipoaspirate in retrograde fashion while pulling the needle out. 20 Mice were imaged using a MicroCAT-II in vivo x-ray micro-computed tomography scanner (Imtek, Inc., Knoxville, Tenn.) 2 days after fat graft injection for baseline volume measurements. Fat graft volume retention was then analyzed every 2 weeks over a total of 8 weeks using micro-computed tomography, and images were reconstructed as three-dimensional surfaces through cubic-spline interpolation, as described previously. 20 All reconstructions were performed by a single investigator (J.F.) to avoid interobserver variability.
Skin Analysis
Scalp skin biopsy specimens were harvested from both treatment groups after completion of irradiation and then 8 weeks after fat grafting. Specimens were fixed in 4% paraformaldehyde, processed, and embedded in paraffin for sectioning. For dermal thickness measurement, sections were stained with hematoxylin and eosin and imaged using a Leica DM5000 B light microscope (Leica Microsystems, Buffalo Grove, Ill.) using the 20× objective. 10 Dermal measurements were made on 10 stained sections from each sample. Picrosirius red staining was also performed for collagen content. Vascularity was determined with CD31 immunofluorescent staining [1:100 Ab28364 (Abcam, Cambridge, Mass.) and 1:200 AF547 (Thermo Fisher Scientific, Waltham, Mass.)] and 4′,6-diamidino-2-phenylindole counterstaining to visualize cell nuclei. Fluorescent images were obtained using an X-Cite 120 Fluorescence Illumination System (Lumen Dyanmics Group, Inc., Ontario, Quebec, Canada) using the 20× objective. Quantification of CD31 staining was performed using ImageJ (National Institutes of Health, Bethesda, Md.), with pixel-positive area per high-power field measured to determine vascular density. 11 Comparisons for both dermal thickness and CD31 immunofluorescent staining were also made to nonirradiated skin.
Statistical Analysis
Data are presented as means ± SE. Two-tailed t test was used for comparison between two groups and an analyses of variance with Tukey post hoc test was used for multiple group comparisons. All analyses were performed using StatPlus software (Analyst-Soft, Inc., Alexandria, Va.). A value of p < 0.05 was considered significant.
RESULTS
Deferoxamine Treatment Effects on Perfusion
Following completion of irradiation and 5-week recovery, perfusion at the scalp was noted to significantly drop from a laser Doppler perfusion index value of 265.23 ± 7.01 (preirradiation baseline) to 176.70 ± 2.59 (Fig. 2) . However, treatment of the scalp with 1 mg of deferoxamine every other day after radiation recovery resulted in an increased laser Doppler perfusion index, which became significant after four treatments (laser Doppler perfusion index, 205.08 ± 2.30 ) (p < 0.05). No increase in laser Doppler perfusion index measurements was noted after four treatments, though, as three additional treatments of deferoxamine did not result in any significant increase in perfusion. In contrast, injection of saline alone resulted in no change to laser Doppler perfusion index measurements over the entire treatment course (Fig. 2 ).
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Deferoxamine Preconditioning and Fat Graft Retention
In vivo radiographic analysis of fat grafts showed that deferoxamine-preconditioned irradiated mice retained more fat volume (89.24 ± 1.69 percent) after 2 weeks compared with saline-injected control mice (74.03 ± 7.91 percent) (Fig. 3) . Fat graft volume retention was consistently greater among deferoxamine-treated mice compared with saline control mice, and at 6 and 8 weeks, these differences were statistically significant: week 6, 73.17 ± 4.26 percent for deferoxamine versus 52.40 ± 4.83 percent for saline; and week 8, 71.75 ± 3.70 percent for deferoxamine versus 49.47 ± 4.62 percent for saline (p < 0.05) (Fig. 3) .
Histologic Effects of Deferoxamine and Fat Grafting on Irradiated Skin
After irradiation and saline control treatment, vascularity in skin biopsy specimens, as demonstrated by CD31 staining, was found to be significantly lower than in nonirradiated healthy skin (p < 0.05) (Fig. 4) . However, treatment of irradiated skin with deferoxamine resulted in increased CD31 staining, although this did not reach healthy skin levels (Fig. 4) . As expected, after fat grafting, skin biopsy specimens obtained after 8 weeks also demonstrated increased CD31 staining compared with control, saline-injected irradiated skin. Interestingly, slightly more CD31 staining following fat grafting was also noted with deferoxamine-preconditioned mice relative to saline control fat-grafted mice, although this difference was not significant (Fig. 4) .
Perfusion of the skin following fat grafting was also measured by laser Doppler analysis, and laser Doppler perfusion index values were found to be lower than immediately after completion of deferoxamine or saline preconditioning because of changes in three-dimensional architecture of the region of interest following placement of fat. However, 2 weeks after injection of fat grafts, significantly more perfusion was still noted in deferoxamine-preconditioned mice (laser Doppler perfusion index, 86.33 ± 2.00 versus 65.72 ± 2.02 for saline control; p < 0.05) (Fig. 5) . Perfusion also continued to increase in the deferoxaminepreconditioned mice following fat grafting, but perfusion similarly increased in saline-injected control mice after fat grafting, and after week 2, no significant difference on laser Doppler analysis was appreciated between the two groups (laser Doppler perfusion index, 127.78 ± 2.29 versus 119.18 ± 4.09 for deferoxamine-and saline-treated mice 8 weeks after grafting, respectively; p > 0.05) (Fig. 5) .
Finally, dermal thickness of irradiated skin following saline treatment was significantly greater than healthy, nonirradiated skin (p < 0.05) (Fig. 6) . Compared with saline-injected mice (256.71 ± 16.76 μm), deferoxamine treatment on irradiated skin resulted in a slight decrease in dermal thickness (242.09 ± 7.22 μm), but this was not significantly Plastic and Reconstructive Surgery • March 2018 less. However, fat grafting, whether into saline-or deferoxamine-preconditioned sites, was found to significantly decrease dermal thickness, although there was no significant difference when comparing these two groups (p > 0.05) (Fig. 6 ). Paralleling these findings, picrosirius red staining revealed a significantly increased collagen content following irradiation and saline treatment (p < 0.05) (Fig. 7) . Deferoxamine treatment on irradiated skin resulted in a slight decrease in collagen content that was not statistically significant. Also, similar to our observations with dermal thickness, fat grafting, whether into saline-or deferoxamine-preconditioned sites, was found to significantly reduce collagen content (p < 0.05) (Fig. 7) .
DISCUSSION
After heart disease, cancer remains the leading cause of death in the United States, with an estimated 1.6 million new cancer cases diagnosed and 600,000 cancer-related deaths projected for 2017. 21 However, in recent years, substantial progress in medical care has been made, with surgery, chemotherapy, and radiation therapy increasing both the number of cancer survivors and the length of their survival. 22 With this improvement, long-term issues related to treatment of cancer, such as with radiation therapy, have become increasingly apparent, and have been shown to profoundly impact quality of life. Radiation-induced soft-tissue injury is one of the most common side effects of radiotherapy, affecting over 90 percent of patients, and the resulting softtissue atrophy and fibrosis can lead to both severe cosmetic and long-term functional impairment. 23, 24 Chronic radiation injury is characterized by epidermal thinning, eosinophilic homogenized sclerosis of dermal collagen, scattered large and atypical fibroblasts, and fibrous thickening with luminal obliteration of deep vessels. [24] [25] [26] Vascular damage and development of fibrosis are thought to result from radiation-induced cytokine expression, generation of reactive oxygen species, and cellular apoptosis, 27 and soft-tissue reconstruction of such hostile sites remains extremely challenging. Although autologous fat grafting has become increasingly popular to address postirradiation soft-tissue deficits, fibroinflammatory changes and hypovascularity have been associated with poorer fat graft outcomes. 10, 11 Improved retention has been noted with cell-assisted lipotransfer, but the functional heterogeneity among stromal cells used to enrich lipoaspirate, in concert with concerns regarding postoncologic locoregional recurrence, has limited the widespread adoption of this strategy.
To improve fat graft outcomes, in this present study we instead focused on preconditioning the irradiated soft-tissue site with deferoxamine to enhance vascularity. HIF-1α is typically degraded by prolyl hydroxylase domain-containing protein 2, and deferoxamine, through chelation of the iron cofactor for prolyl hydroxylase domain-containing protein 2 activity, has been shown to stabilize HIF-1α, leading 
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to an increase in downstream angiogenic factors and recruitment of endothelial progenitor cells. 28, 29 This is the mechanism by which deferoxamine has been thought to promote revascularization of ischemic skin flaps; enhance wound healing in diabetic mice 15, 30 ; and augment callus size, mineralization, and mechanical strength at irradiated bone injury sites. 31, 32 Furthermore, reversal of radiation-induced hypovascularity has also been appreciated with deferoxamine treatment during mandibular distraction osteogenesis. 17, 33 All of these findings support the potential for deferoxamine, through stabilization of HIF-1α and increased angiogenic gene expression, to precondition the irradiated recipient site for subsequent fat grafting.
Importantly, deferoxamine was recently suggested to promote fat graft viability in a rat model. Temiz and colleagues described serial injections of 300 mg of deferoxamine into inguinal fat pads transplanted to parascapular subcutaneous pockets, which resulted in significantly greater weight measurements after 2 months. 12 However, more inflammation and fibrosis was noted in deferoxamine-injected fat grafts, although no change in cellular apoptosis was appreciated. Repeated manipulation of fat grafts with each injection may have contributed to this observation. In addition, adipogenic differentiation of resident stromal cells has been purported to contribute to longterm fat graft retention, 34, 35 and direct exposure of deferoxamine to fat grafts may be detrimental to this process. Studies have shown intracellular iron deficiency through deferoxamine administration to severely blunt adipocyte differentiation. 36 These findings thus temper enthusiasm for direct injection of deferoxamine into fat grafts. Alternatively, preconditioning the recipient site to facilitate earlier revascularization of fat grafts remains promising, and this study, to our knowledge, is the first to analyze the effects of deferoxamine local injections to irradiated, hypovascular skin. We noted improved perfusion by laser Doppler analysis of irradiated tissue with deferoxamine treatment. Importantly, laser Doppler analysis allowed for the estimation of in vivo local blood perfusion in the microcirculation through frequency shifts in light that has been scattered by moving red blood cells. This facilitated longitudinal measurements in the same animal following each treatment with deferoxamine. Histologic analysis of treated skin also revealed increased vascularity by CD31 staining following deferoxamine treatment. This translated to enhanced volume retention when fat grafts were placed into deferoxamine-preconditioned recipient sites. Interestingly, the addition of fat grafts to deferoxamine-treated irradiated tissue led to further improvement in vascularity, even though deferoxamine-related effects were seen to plateau after four treatments. This suggests that alternative mechanisms may also be used by transferred adipocytes and associated stromal cells to improve vascularity following fat grafting. 
Finally, the effects of deferoxamine treatment on skin vascularity were not found to be associated with significant changes to dermal thickness and collagen content. Decreased dermal thickness and collagen content were noted, however, following fat grafting, as reported previously. 10, 11 Therefore, the architectural changes observed in the dermis with decreased collagen secondary to fat transfer may not necessarily be a result of improved vascularity alone.
Although the treatment protocol for deferoxamine preconditioning of irradiated tissue used in our study follows other previously published reports, delivery of deferoxamine on alternate dates through direct injection may limit the clinical translation of this approach. In patients with radiation fibrosis and soft-tissue atrophy, preconditioning tissue with serial deferoxamine injections before fat grafting may be difficult logistically and not well tolerated by patients. However, recent description of a transdermal drug delivery system for deferoxamine was found to improve wound healing and prevent pressure-induced ulcer formation in diabetic mice. 13 Such an approach may also be potentially effective at preconditioning irradiated tissue for fat grafting and would likely be better tolerated by patients. Alternatively, nanoparticle formulations of deferoxamine have also been developed, and their controlled release of deferoxamine may similarly be used to improve vascularity of irradiated skin. These nanoparticles may also be directly injected with fat grafts to promote earlier revascularization.
As deferoxamine promotes expression of multiple angiogenic factors through stabilization of HIF-1α, concern may also be raised regarding its use in irradiated postoncologic resection sites. Although no studies, to our knowledge, have demonstrated an increased risk for cancer recurrence following local administration of deferoxamine, several reports have suggested an antitumor effect. Iron is necessary for oxygen transport, cell metabolism, and growth, and it is especially important in cells with active growth. 37, 38 Not surprisingly, iron chelators such as deferoxamine have been found to reduce liver fibrosis, and its effect on iron metabolism has been shown to clinically reduce progression of hepatocellular carcinoma. [39] [40] [41] Iron dependency has also been reported in human epidermal growth factor receptor-2-positive breast cancer cells, and multiple breast cancer cell lines have been shown to be vulnerable to iron chelation. 42 These reports thus suggest local deferoxamine application may not be associated with increased risk for cancer recurrence.
Collectively, our findings demonstrate that deferoxamine treatment can improve radiation therapy-induced hypovascularity, and this enhanced perfusion may improve the quality of the recipient site for fat grafting. In our study, the effects of deferoxamine on vascularity were noted to plateau after four treatments, and it remains unknown whether the improved flow is durable after deferoxamine withdrawal. Another limitation of this study is with deferoxamine dosage and treatment regimen. Although these were selected based on previously published studies in other models, 15, 17, 18, 31 whether a higher or lower dosage administered more or less frequently would result in increased or decreased vascularity is also unknown. Despite this, after deferoxamine treatment, long-term retention of fat grafts injected into irradiated sites was significantly improved.
CONCLUSIONS
Reconstruction of irradiated tissue remains challenging because of radiation-induced alterations to the recipient bed. Fibroinflammatory changes and hypovascularity have been shown to impact fat graft retention, and although cellbased strategies have been shown to improve outcomes, regulatory and safety concerns have, to date, limited their translational potential. As an alternative approach, we have demonstrated that preconditioning irradiated tissue with deferoxamine improves local perfusion, and this was associated with improved radiographic and histologic fat graft outcomes. Preconditioning with deferoxamine before fat grafting therefore holds promise for enhancing reconstruction outcomes for irradiated tissue. 
